Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Sarah-Cannon-Research-Institute-in-Nashville"

1 News Found

Arvinas and Pfizer announce updated clinical data from Phase 1b Trial of Vepdegestrant in combination with Palbociclib
Diagnostic Center | May 18, 2024

Arvinas and Pfizer announce updated clinical data from Phase 1b Trial of Vepdegestrant in combination with Palbociclib

At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months